Legal & General Group Plc boosted its position in Genomic Health, Inc. (NASDAQ:GHDX) by 48.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,222 shares of the medical research company’s stock after buying an additional 2,038 shares during the period. Legal & General Group Plc’s holdings in Genomic Health were worth $196,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of GHDX. Dubuque Bank & Trust Co. bought a new position in Genomic Health during the first quarter valued at approximately $142,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Genomic Health during the first quarter valued at approximately $218,000. Stonebridge Capital Management Inc. bought a new position in Genomic Health during the first quarter valued at approximately $259,000. Envestnet Asset Management Inc. raised its position in Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after buying an additional 993 shares during the period. Finally, Wetherby Asset Management Inc. raised its position in Genomic Health by 4.1% in the first quarter. Wetherby Asset Management Inc. now owns 8,595 shares of the medical research company’s stock valued at $271,000 after buying an additional 340 shares during the period. Institutional investors and hedge funds own 89.53% of the company’s stock.

Shares of Genomic Health, Inc. (NASDAQ GHDX) traded up 1.00% during trading on Friday, hitting $30.22. The company’s stock had a trading volume of 79,065 shares. The firm’s 50 day moving average is $32.22 and its 200-day moving average is $31.13. Genomic Health, Inc. has a 1-year low of $25.66 and a 1-year high of $33.97. The company’s market capitalization is $1.05 billion.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same quarter in the prior year, the business posted ($0.18) EPS. Genomic Health’s revenue was up 4.3% compared to the same quarter last year. Analysts forecast that Genomic Health, Inc. will post $0.01 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Legal & General Group Plc Raises Stake in Genomic Health, Inc. (GHDX)” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/12/legal-general-group-plc-raises-stake-in-genomic-health-inc-ghdx.html.

Several research firms recently commented on GHDX. Jefferies Group LLC reissued a “hold” rating and set a $33.00 price target on shares of Genomic Health in a research report on Monday, June 12th. BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Piper Jaffray Companies reissued a “hold” rating and set a $31.00 price target on shares of Genomic Health in a research report on Thursday, August 3rd. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Raymond James Financial, Inc. reissued a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $32.43.

In related news, CEO Kimberly J. Popovits sold 1,468 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $32.67, for a total transaction of $47,959.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James J. Vaughn sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total value of $244,720.00. The disclosure for this sale can be found here. Insiders sold a total of 75,642 shares of company stock valued at $2,342,466 in the last quarter. Corporate insiders own 46.20% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.